Osteonecrosis, also called aseptic necrosis or bone necrosis, is defined in the packet as a disease characterized by death of bone tissue due to a lack of blood supply. The packet lists several disease subtypes, including avascular necrosis, osteonecrosis of genetic origin, osteochondrosis, and osteoradionecrosis, indicating that the term covers a group of related conditions.

The packet contains no phenotype annotations with frequency data and no age-of-onset categories for osteonecrosis. The only clinical description available is the definition, which refers to death of bone tissue. Specific symptoms, their frequency, and their severity are not certified in this packet.

The definition attributes osteonecrosis to a lack of blood supply to bone, resulting in death of bone tissue. The packet lists no known genes and no inheritance patterns, although one listed subtype is named osteonecrosis of genetic origin; its genetic basis is not specified here.

The packet does not include diagnostic methods or a GeneReviews diagnosis section for osteonecrosis. How the condition is identified is not certified in this packet.

The packet lists no FDA-approved treatments for osteonecrosis, and no GeneReviews management content is present. The orphan drug list contains cell-based products with the status DESIGNATED for treatment of osteonecrosis: autologous adult live cultured osteoblasts (Regrow Biosciences Pvt. Ltd.), human allogeneic bone marrow derived osteoblastic cells (Biosenic SA), and tissue repair cells obtained from autologous bone marrow expanded ex vivo (Aastrom Biosciences, Inc.). An orphan designation is not an approval, and the packet does not establish that these products are available treatments. A further product, a human autologous bone-forming cell derived from bone marrow stem cells (Bone Therapeutics S.A.), carries the status WITHDRAWN and is not a current option. Absence of other treatment information reflects this packet only.

Prognosis and natural history are not certified in this packet. No information on progression or outcomes is available beyond the definition.

The packet certifies active clinical trial records associated with osteonecrosis. Records listed include a study titled Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis (Johns Hopkins University, recruiting), a study titled Safety, Tolerability, and Preliminary Efficacy of Intra-Articular Injection of Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Non-Traumatic Avascular Necrosis of the Femoral Head (Beijing Jishuitan Hospital, not yet recruiting). Other listed titles refer to prosthesis systems, arthroplasty, or hyperbaric oxygen and do not by themselves establish the intervention studied or its relevance. The trial intervention summary lists drug therapy, medical devices, procedural interventions, and other interventions.